Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
Pathol Int. 2022 Aug;72(8):402-410. doi: 10.1111/pin.13255. Epub 2022 Jun 28.
Paired-like homeobox 2b (PHOX2B) is an established immunomarker for peripheral neuroblastoma and autonomic nervous system cells. We aimed to evaluate the utility of PHOX2B immunostaining in central nervous system (CNS) tumors with embryonal morphology. Fifty-one tumors were stained with PHOX2B and submitted for whole slide image analysis: 35 CNS tumors with embryonal morphology (31 CNS embryonal tumors and four gliomas); and 16 peripheral neuroblastomas were included for comparison. Diffuse nuclear immunopositivity was observed in all (16/16) neuroblastomas (primary and metastatic). Among CNS embryonal tumors, focal immunoreactivity for PHOX2B was observed in most (5/7) embryonal tumors with multilayered rosettes (ETMR) and a single high-grade neuroepithelial tumor (HGNET) with PLAGL2 amplification; the remaining 27 CNS tumors were essentially immunonegative (<0.05% positive). Among ETMR, PHOX2B expression was observed in a small overall proportion (0.04%-4.94%) of neoplastic cells but focally reached up to 39% in 1 mm 'hot spot' areas. In the PLAGL2-amplified case, 0.09% of the total neoplastic population was immunoreactive, with 0.53% in the 'hot spot' area. Care should be taken in interpreting PHOX2B immunopositivity in a differential diagnosis that includes metastatic neuroblastoma and CNS tumors; focal or patchy expression should not be considered definitively diagnostic of metastatic peripheral neuroblastoma.
配对盒基因 2B(PHOX2B)是外周神经母细胞瘤和自主神经系统细胞的公认免疫标志物。我们旨在评估 PHOX2B 免疫染色在具有胚胎形态的中枢神经系统(CNS)肿瘤中的应用。对 51 例肿瘤进行了 PHOX2B 染色,并进行了全切片图像分析:35 例具有胚胎形态的 CNS 肿瘤(31 例 CNS 胚胎肿瘤和 4 例神经胶质瘤);和 16 例外周神经母细胞瘤作为比较。所有(16/16)神经母细胞瘤(原发性和转移性)均观察到弥漫性核免疫阳性。在 CNS 胚胎肿瘤中,大多数(5/7)具有多层玫瑰花结的胚胎肿瘤(ETMR)和 1 例具有 PLAGL2 扩增的高级别神经上皮肿瘤(HGNET)观察到 PHOX2B 免疫反应性局灶性;其余 27 例 CNS 肿瘤基本上为免疫阴性(<0.05%阳性)。在 ETMR 中,PHOX2B 表达在肿瘤细胞中的总体比例较小(0.04%-4.94%),但在 1mm 的“热点”区域可达到高达 39%。在 PLAGL2 扩增的病例中,总肿瘤人群中有 0.09%为免疫反应性,“热点”区域有 0.53%。在包括转移性神经母细胞瘤和 CNS 肿瘤的鉴别诊断中,应谨慎解释 PHOX2B 免疫阳性;局灶性或斑片状表达不应被认为是转移性外周神经母细胞瘤的明确诊断。